Skip to content
RecallWatchMedical Device Safety
Class IOngoingZ-1646-2026

Philips Respironics, Inc. recalls Philips Respironics Trilogy Evo

Philips Respironics, Inc.Murrysville, PA, United StatesReported Apr 8, 2026 · 4 months ago
Legal News Analyst ·

Reason for recall

In some situations, the Obstruction Alarm does not trigger within the timeframe dictated by the relevant standards and may take up to four breaths.

Affected product

Check your device

Enter a lot, serial, REF, or UDI number from your device's label to check it against this recall's listed codes.

Philips Respironics Trilogy Evo, Software Version 1.05.15.00. Continuous home-use ventilator device.

Lot / code information

Model
; All
UDI
; All

What the firm is doing

An IMPORTANT PRODUCT NOTICE was mailed to consignees 6/5/24 about obstruction alarm compliance failure in Trilogy Evo devices. Refer to the most current version of the IFU in the event of an obstruction. A software update to correct this issue is pending. An UPDATED: URGENT FIELD SAFETY NOTICE was mailed 3/2/26 with recall information for three failure modes possible in all Trilogy Evo, Trilogy EVO O2, Trilogy Evo Universal, and Trilogy EV300. Using non-pneumatic nebulizers with Trilogy Evo Platform ventilators may result in a discrepancy between the set tidal volume and the tidal volume received by the patient. This can lead to under-delivery of therapy to the patient. Update all devices with software version 1.05.15.00 through the My Philips for Professionals and InCenter websites. Stop use of non-pneumatic nebulizers, including vibrating mesh nebulizers, with all affected devices. Distributors give your customers the provided recall notice and response form. DME and Homecare Customers call 1-800-345-6443 (option 2, option 1) for assistance. Hospital Customers call 1-800-722-9377 (option 2) for assistance. **An UPDATED: URGENT FIELD SAFETY NOTICE was mailed to consignees 4/24/26 with recall information for three failure modes possible in all Trilogy Evo, Trilogy EVO O2, Trilogy Evo Universal, and Trilogy EV300 devices. It clarifies and revises guidance about the use of non-pneumatic nebulizers with Trilogy Evo Platform ventilators communicated in the 3/2/26 update. This does not change this previously communicated information: Nebulized aerosol deposition on the internal flow sensor (FSN 2024-CC-SRC-013 - Flow Sensor Nebulized Aerosol Deposition), and Obstruction Alarm timing (IPN 2024-CC-SRC-002 - Obstruction Alarm). Consignees review the latest version of the User Manual Addendum, give the safety notice to all who interact with affected devices, and forward the notice to those to whom product was further distributed.

DistributionShow details

Worldwide Distribution. US Nationwide, Argentina, Austria, Australia, Bosnia and Herzegovina, Bangladesh, Belgium, Bulgaria, Bolivia, Brazil, Bahamas, Canada, Switzerland, Chile, China, Colombia, Czech Republic, Germany, Denmark, Algeria, Ecuador, Estonia, Egypt, Spain, Finland, France, Georgia, French Guiana, Gibraltar, Greece, Guatemala, Hong Kong, Croatia, Hungary, Indonesia, Ireland, Israel, India, Italy, Jersey, Jordan, Japan, Kenya, South Korea, Kuwait, Lebanon, Lithuania, Morocco, Montenegro, North Macedonia, Myanmar, Martinique, Malta, Mexico, Malaysia, Nigeria, Netherlands, Norway, Nepal, New Zealand, Oman, Panama, Peru, French Polynesia, Philippines, Pakistan, Poland, Portugal, Paraguay, Qatar, Reunion, Romania, Serbia, Russia, Saudi Arabia, Sweden, Singapore, Slovenia, Slovakia, Thailand, Tunisia, Turkey, Taiwan, Ukraine, United Arab Emirates, United Kingdom, Vietnam, Mayotte, South Africa, Zimbabwe.

Class IWhat this means

A reasonable probability that use of the product will cause serious adverse health consequences or death.

Sources & references

Taylor Coteus
Legal News Analyst

Taylor Coteus is RecallWatch's Legal News Analyst, covering FDA medical-device enforcement and patient-safety litigation. He reviews every recall against the FDA's official openFDA record before it is published and is responsible for corrections and editorial accuracy.

More Class I recalls

Class IOngoingZ-2879-2026

Boston Scientific Neuromodulation Corporation recalls INFINION CX LEAD KIT

Spinal cord stimulation system lead body may be exposed to stress at the anchor site. This may result in high impedance measurements or lead fractures, which may lead to inadequate stimulation, additional intervention, i…

  • Totally Implanted For Pain Relief Spinal-Cord Stimulator
  • Device Design
Boston Scientific Neur…CAAug 12, 2026